Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis

Phase 3CompletedNCT00421915

Wyeth is now a wholly owned subsidiary of Pfizer84 enrolled

Overview

The primary objective of the study was to compare the efficacy of etanercept (25 mg, twice weekly) with that of placebo based on the percentage of patients who achieve the Assessment in Ankylosing Spondylitis (ASAS) response criteria (ASAS 20%) at week 12.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Ankylosing Spondylitis

Interventions

Enbrel (etanercept)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Main inclusion criteria * Diagnosis of AS (defined by Modified New York Criteria for Ankylosing Spondylitis). * Active AS (defined by the average of scores on the visual analog scale \[VAS\] of ≥ 30 for duration and intensity of morning stiffness and by 2 of the following: VAS for patient global assessment ≥ 30; average of VAS for nocturnal and total pain ≥ 30; BASFI ≥ 30 (all scores on a scale of 0 to 100). * 18 to 70 years of age. Main exclusion criteria * Complete ankylosis (fusion) of spine. * Previous receipt of etanercept, antibody to tumour necrosis factor alpha (TNFα), or other TNFα inhibitors. * Use of disease-modifying antirheumatic drugs (DMARDs) other than hydroxychloroquine, sulphasalazine, or methotrexate within 4 weeks of baseline.

Outcomes

Primary Outcomes

To compare the efficacy of etanercept (25 mg, twice weekly) with that of placebo based on the

percentage of patients who achieved the assessment in Ankylosing Spondylitis (ASAS 20%) response criteria at week 12.

Secondary Outcomes

To assess: 1) the safety of etanercept in this patient population; 2) the efficacy of etanercept

compared with that of placebo using the ASAS response criteria at 50% and 70% levels at week 12.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.